Cerebrolysin
A mix of brain-derived peptides and amino acids from pig brains. Widely used worldwide for stroke recovery, brain injury, and brain degeneration. Mimics the body's natural brain-supporting factors to help neurons survive, form new connections, and grow.
Dosage
Cognitive: 5-10 mL IM daily. Stroke/TBI: 10-30 mL IV daily for 10-20 days
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Half-Life
Peptide fragments: minutes to hours; neurotrophic effects persist for days
Half-Life Calculator →Administration
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Neurotrophic Support
Mimics BDNF, NGF, CNTF, and GDNF — approved in 50+ countries for neurological conditions.
Neuroprotection
Reduces amyloid-beta aggregation and tau hyperphosphorylation in Alzheimer's models.
Neurogenesis
Stimulates new neuron production in hippocampal dentate gyrus.
Mechanism of Action
Cerebrolysin is a complex biological preparation consisting of low-molecular-weight neuropeptides (approximately 75%) and free amino acids (approximately 25%), derived from enzymatic breakdown of porcine brain tissue. The peptide fraction contains fragments that mimic the activity of endogenous neurotrophic factors — BDNF, NGF, ciliary neurotrophic factor (CNTF), and glial cell line-derived neurotrophic factor (GDNF) — without being identical to any single neurotrophin.
The neurotrophic peptide components activate canonical neurotrophin signaling pathways. BDNF-mimetic peptides bind TrkB receptors, activating PI3K/Akt (cell survival) and Ras/MAPK/ERK (synaptic plasticity) cascades. NGF-mimetic peptides activate TrkA receptors on cholinergic neurons, supporting their survival and acetylcholine production. The combined neurotrophic activity promotes neuronal survival in ischemic and degenerative conditions, enhances synaptic plasticity and dendritic branching, and stimulates neurogenesis in the subgranular zone of the hippocampal dentate gyrus — one of the two brain regions where new neurons are produced in adults.
In Alzheimer's disease, Cerebrolysin has demonstrated multiple disease-modifying effects in preclinical and clinical studies. It reduces amyloid-beta aggregation by modulating the activity of amyloid precursor protein (APP) processing enzymes, shifting cleavage toward the non-amyloidogenic alpha-secretase pathway. It also reduces tau hyperphosphorylation by inhibiting glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (CDK5), the primary kinases responsible for the pathological phosphorylation of tau that leads to neurofibrillary tangle formation. In acute stroke, Cerebrolysin provides neuroprotection against glutamate excitotoxicity by modulating NMDA receptor activity — reducing excessive calcium influx through the receptor while preserving physiological glutamatergic signaling needed for normal neuronal function. Its approval in over 50 countries and large clinical evidence base (including meta-analyses of randomized controlled trials) make it one of the most clinically validated neuropeptide preparations, despite its lack of FDA approval.
Regulatory Status
Approved in 50+ countries (Europe, Asia, Latin America) for stroke, TBI, and dementia. Not FDA approved. Manufactured by EVER Pharma (Austria). Large clinical evidence base but limited US acceptance.
Risks & Safety
Common
dizziness, headache, injection site pain, sweating, mild nausea.
Serious
can lower seizure threshold (not safe for people with epilepsy), agitation and confusion (especially in elderly), fever.
Rare
severe allergic reaction (made from pig brains — not suitable for people with pork allergies), severe agitation.
Compare Cerebrolysin With
Research Papers
30Published: November 6, 2025
AI Summary
Cerebrolysin reversed anxiety and memory problems in ketamine-treated mice by restoring mitochondrial function and boosting CREB/PGC-1α. The findings suggest a pathway for treating schizophrenia-related cognitive deficits.
Published: July 7, 2025
AI Summary
A scoping review found limited evidence for cerebrolysin in mental health. It may help with depression and autism and reduce side effects of antipsychotic drugs.
Published: July 15, 2025
AI Summary
Researchers examined cerebrolysin's effects on behavior and inflammation in a schizophrenia mouse model. The abstract describes the study aim; full results would clarify effects on the tryptophan-kynurenine pathway.
Published: April 21, 2025
AI Summary
Cerebrolysin reduced harmful cytokines and raised protective ones in brain cells under stroke-like conditions. The work supports its use for stroke, traumatic brain injury, and related disorders.
Published: March 23, 2025
AI Summary
Cerebrolysin restored dendritic structure and BDNF in the amygdala of rats with early-life stress. The work suggests it could help reverse stress-related brain changes in youth.
Published: March 4, 2025
AI Summary
A review discusses cerebrolysin's potential for vascular dementia by targeting inflammation, blood-brain barrier damage, and poor blood flow. The work outlines possible mechanisms and therapeutic role.
Published: November 23, 2024
AI Summary
Cerebrolysin improved motor function in rats with motor cortex damage by promoting neuronal plasticity and raising GAP43. The work suggests it could support motor recovery after brain injury.
Published: July 17, 2024
AI Summary
A patient had a severe allergic reaction to cerebrolysin that was successfully treated. The case highlights that anaphylaxis can occur with this drug and that prompt recognition is important.
Published: January 6, 2024
AI Summary
Other peptide preparations marketed as similar to Cerebrolysin lacked its biological activity and had different compositions. The work cautions against assuming generic equivalents are interchangeable.
Published: June 20, 2024
AI Summary
Combining cerebrolysin and nicotinamide improved cognition and reduced stroke damage in rats. The combination promoted neuronal changes and BDNF, suggesting a promising stroke treatment.
Published: April 16, 2024
AI Summary
Researchers tested whether cerebrolysin enhances lithium's antidepressant effect in depressed rats. The abstract describes the study aim; full results would clarify potential as adjunct therapy.
Published: October 22, 2023
AI Summary
Cerebrolysin protected nerve cells from high-glucose damage and supported neurite growth. The work suggests it could help treat diabetic nerve damage in peripheral sensory neurons.
Published: February 6, 2024
AI Summary
Cerebrolysin extended lifespan and improved memory in a mouse model of CADASIL, though it did not reverse the specific white matter changes. The drug may help disorders marked by accelerated aging.
Published: December 8, 2023
AI Summary
Researchers evaluated cerebrolysin plus smell and taste training for persistent post-COVID smell and taste loss. The abstract describes the study aim; full results would clarify efficacy.
Published: September 25, 2023
AI Summary
Spinal cord injury raised amyloid and tau in the brain and cord; nanowired cerebrolysin plus antibodies reduced these changes and barrier damage. The work links spinal trauma to Alzheimer-like pathology and a possible treatment.
Published: October 10, 2023
AI Summary
A Cochrane review update summarizes evidence on cerebrolysin for acute stroke. The abstract describes the review scope; full results would clarify efficacy and safety.
Published: September 14, 2023
AI Summary
Nanowired cerebrolysin plus antibodies to tau and nNOS reduced brain pathology in a Parkinson model worsened by head injury. The combination may help veterans with concussion-related neurodegeneration.
Published: September 15, 2023
AI Summary
Stress worsened Alzheimer-like brain changes in rats; nanowired cerebrolysin plus amyloid antibodies and a serotonin blocker reversed this. The work suggests a treatment strategy for stress-aggravated dementia.
Published: September 21, 2023
AI Summary
Nanowired cerebrolysin plus antibodies to amyloid, tau, and serotonin reduced brain pathology caused by sleep deprivation. The work suggests a way to limit sleep-loss-related Alzheimer-like changes.
Published: July 27, 2023
AI Summary
Cerebrolysin given after forebrain ischemia-reperfusion improved neurologic function and reduced inflammation and cell death. It worked partly by activating antioxidant pathways.
Published: July 23, 2023
AI Summary
Nanowired Ginkgo biloba extract plus cerebrolysin improved outcomes after spinal cord injury in cold-acclimated rats. The combination may help in cold-environment trauma.
Published: July 23, 2023
AI Summary
Nanowired delivery of stem cells plus cerebrolysin reduced brain damage from blast injury in heat-stressed rats. The work suggests a treatment for military blast injury in hot environments.
Published: October 22, 2023
AI Summary
Nanowired cerebrolysin plus stem cells and nNOS antibodies reduced Alzheimer-like brain pathology worsened by head injury. The combination may help concussion-related dementia.
Published: July 23, 2023
AI Summary
Nanowired antibodies to amyloid, tau, and TNF-α reduced Alzheimer-like brain pathology caused by sleep deprivation. The work suggests a treatment for sleep-loss-related dementia.
Published: May 31, 2023
AI Summary
Researchers identified neuroprotective peptides in Cerebrolysin, including anti-inflammatory and antioxidant sequences. The work helps clarify which components may drive its therapeutic effects.
Published: July 31, 2023
AI Summary
Fucoidan plus cerebrolysin reduced stroke damage and inflammation in rats better than either drug alone. The combination preserved the blood-brain barrier and improved recovery.
Published: September 12, 2023
AI Summary
A review describes how neurotrophic factors and Cerebrolysin affect brain repair in dementia, stroke, and TBI. It outlines their roles in plasticity, inflammation, and possible treatment.
Published: June 30, 2023
AI Summary
Cerebrolysin reduced neuropathic pain and spinal cord damage in rats with nerve injury, including when worsened by metal nanoparticles. The work suggests a treatment for complex pain syndromes.
Published: November 3, 2022
AI Summary
Cerebrolysin protected neurons from glutamate toxicity by restoring glutamate transporters and lowering oxidative stress and inflammation. The work clarifies a mechanism for its neuroprotective effects.
Published: September 26, 2022
AI Summary
Researchers examined how cerebrolysin and donepezil affect amyloid and tau in blood vesicles from Alzheimer patients. The abstract describes the study focus; full results would clarify biomarker and treatment effects.
Frequently Asked Questions
What is Cerebrolysin?
A mix of brain-derived peptides and amino acids from pig brains. Widely used worldwide for stroke recovery, brain injury, and brain degeneration. Mimics the body's natural brain-supporting factors to help neurons survive, form new connections, and grow.
What is Cerebrolysin used for?
A mix of brain-derived peptides and amino acids from pig brains. Widely used worldwide for stroke recovery, brain injury, and brain degeneration. Mimics the body's natural brain-supporting factors to help neurons survive, form new connections, and grow.
What is the dosage for Cerebrolysin?
Cognitive support: 5-10 mL intramuscular once daily. Stroke/TBI: 10-30 mL IV infusion over 15-60 minutes once daily. Typical treatment course: 10-20 days. May be repeated after a 4-8 week interval.
What are the side effects of Cerebrolysin?
Common: dizziness, headache, injection site pain, sweating, mild nausea. Serious: can lower seizure threshold (not safe for people with epilepsy), agitation and confusion (especially in elderly), fever. Rare: severe allergic reaction (made from pig brains — not suitable for people with pork allergies), severe agitation.
How does Cerebrolysin work?
Cerebrolysin is a complex biological preparation consisting of low-molecular-weight neuropeptides (approximately 75%) and free amino acids (approximately 25%), derived from enzymatic breakdown of porcine brain tissue. The peptide fraction contains fragments that mimic the activity of endogenous neurotrophic factors — BDNF, NGF, ciliary neurotrophic factor (CNTF), and glial cell line-derived neurotrophic factor (GDNF) — without being identical to any single neurotrophin. The neurotrophic peptide components activate canonical neurotrophin signaling pathways. BDNF-mimetic peptides bind TrkB receptors, activating PI3K/Akt (cell survival) and Ras/MAPK/ERK (synaptic plasticity) cascades. NGF-mimetic peptides activate TrkA receptors on cholinergic neurons, supporting their survival and acetylcholine production. The combined neurotrophic activity promotes neuronal survival in ischemic and degenerative conditions, enhances synaptic plasticity and dendritic branching, and stimulates neurogenesis in the subgranular zone of the hippocampal dentate gyrus — one of the two brain regions where new neurons are produced in adults. In Alzheimer's disease, Cerebrolysin has demonstrated multiple disease-modifying effects in preclinical and clinical studies. It reduces amyloid-beta aggregation by modulating the activity of amyloid precursor protein (APP) processing enzymes, shifting cleavage toward the non-amyloidogenic alpha-secretase pathway. It also reduces tau hyperphosphorylation by inhibiting glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (CDK5), the primary kinases responsible for the pathological phosphorylation of tau that leads to neurofibrillary tangle formation. In acute stroke, Cerebrolysin provides neuroprotection against glutamate excitotoxicity by modulating NMDA receptor activity — reducing excessive calcium influx through the receptor while preserving physiological glutamatergic signaling needed for normal neuronal function. Its approval in over 50 countries and large clinical evidence base (including meta-analyses of randomized controlled trials) make it one of the most clinically validated neuropeptide preparations, despite its lack of FDA approval.
How is Cerebrolysin administered?
Cerebrolysin is administered via intramuscular or intravenous injection.
What is the half-life of Cerebrolysin?
The half-life of Cerebrolysin is Peptide fragments: minutes to hours; neurotrophic effects persist for days.
Is Cerebrolysin legal?
Approved in 50+ countries (Europe, Asia, Latin America) for stroke, TBI, and dementia. Not FDA approved. Manufactured by EVER Pharma (Austria). Large clinical evidence base but limited US acceptance.
Related Peptides
Cortagen
A short synthetic peptide (Ala-Glu-Asp-Pro) developed by the Khavinson Institute in Russia. Designed to support brain cortex function by modulating gene expression in brain cells. Part of the Khavinson peptide bioregulator family alongside Epithalon and Vilon. One of the few peptides specifically formulated for brain function optimization, available in both injectable and oral/sublingual forms.
Dihexa
A compound derived from angiotensin IV, reported to be extremely potent at enhancing memory and brain plasticity in animal studies. One of the most discussed nootropic compounds for memory enhancement. Works through a different pathway than typical brain drugs — the HGF/c-Met system rather than traditional neurotransmitter pathways.
Humanin
A 24-amino-acid peptide naturally produced by mitochondria. Related to MOTS-c but works differently. Protects cells against oxidative stress, cell death, and age-related damage by interacting with proteins involved in apoptosis and IGF signaling. One of the most studied peptides in longevity research, with evidence that levels decline in aging tissues.
Oxytocin
Often called the 'love hormone' — it plays a big role in bonding, trust, and feeling close to others. Your body makes it in the brain. It's also what makes the uterus contract during childbirth and triggers milk release when breastfeeding. The nasal spray form is increasingly used to support social connection and mood.